[SCHEDULE 13G/A] Cidara Therapeutics, Inc. SEC Filing
Cidara Therapeutics, Inc. (CDTX) received a Schedule 13G/A reporting that Point72-affiliated entities and Steven A. Cohen beneficially own 1,527,930 shares of common stock, representing 7.6% of the outstanding class as of June 30, 2025. The filing states those shares are held for investment by Point72 Associates and that Point72 Asset Management and Point72 Capital Advisors maintain shared voting and dispositive power over the shares; none of the reporting persons claim sole voting or dispositive power. The reporting address is 72 Cummings Point Road, Stamford, CT.
Cidara Therapeutics, Inc. (CDTX) ha ricevuto una comunicazione Schedule 13G/A secondo cui entità affiliate a Point72 e Steven A. Cohen detengono beneficiariamente 1.527.930 azioni ordinarie, pari al 7,6% del capitale sociale in circolazione alla data del 30 giugno 2025. La dichiarazione indica che le azioni sono detenute a scopo d'investimento da Point72 Associates e che Point72 Asset Management e Point72 Capital Advisors esercitano congiuntamente il potere di voto e il potere dispositiv o sulle azioni; nessuno dei soggetti segnalanti dichiara poteri di voto o dispositivi esclusivi. L'indirizzo comunicato è 72 Cummings Point Road, Stamford, CT.
Cidara Therapeutics, Inc. (CDTX) recibió una presentación Schedule 13G/A que reporta que entidades afiliadas a Point72 y Steven A. Cohen poseen beneficiariamente 1.527.930 acciones ordinarias, lo que representa el 7,6% de la clase en circulación al 30 de junio de 2025. La presentación señala que esas acciones se mantienen con fines de inversión por Point72 Associates y que Point72 Asset Management y Point72 Capital Advisors comparten el poder de voto y el poder dispositi vo sobre las acciones; ninguno de los informantes reclama poder de voto o dispositi vo exclusivo. La dirección declarada es 72 Cummings Point Road, Stamford, CT.
Cidara Therapeutics, Inc. (CDTX)는 Point72 계열사들과 Steven A. Cohen이 1,527,930주의 보통주를 실질적으로 보유하고 있으며, 이는 2025년 6월 30일 기준 발행 주식의 7.6%에 해당한다고 보고하는 Schedule 13G/A를 접수했습니다. 제출서에는 해당 주식이 투자 목적으로 Point72 Associates 명의로 보유되어 있고 Point72 Asset Management 및 Point72 Capital Advisors가 해당 주식에 대한 공동의 의결권 및 처분권을 보유한다고 기재되어 있습니다; 보고인들 중 어느 누구도 단독 의결권이나 단독 처분권을 주장하지 않습니다. 보고된 주소는 72 Cummings Point Road, Stamford, CT입니다.
Cidara Therapeutics, Inc. (CDTX) a reçu un dépôt Schedule 13G/A indiquant que des entités affiliées à Point72 et Steven A. Cohen détiennent à titre bénéficiaire 1 527 930 actions ordinaires, représentant 7,6% de la catégorie en circulation au 30 juin 2025. Le document précise que ces actions sont détenues à des fins d'investissement par Point72 Associates et que Point72 Asset Management et Point72 Capital Advisors exercent conjointement le pouvoir de vote et le pouvoir de disposition sur ces actions ; aucun des déclarants ne revendique de pouvoir de vote ou de disposition exclusif. L'adresse déclarée est 72 Cummings Point Road, Stamford, CT.
Cidara Therapeutics, Inc. (CDTX) hat eine Schedule 13G/A eingereicht erhalten, die berichtet, dass Point72-nahe Einheiten und Steven A. Cohen wirtschaftlich 1.527.930 Aktien des Stammkapitals besitzen, was 7,6% der ausstehenden Aktienklasse zum 30. Juni 2025 entspricht. Die Einreichung besagt, dass diese Aktien von Point72 Associates zu Anlagezwecken gehalten werden und dass Point72 Asset Management und Point72 Capital Advisors gemeinsame Stimm- und Verfügungsrechte über die Aktien ausüben; keiner der meldenden Personen beansprucht alleiniges Stimm- oder Verfügungsrecht. Die angegebene Anschrift lautet 72 Cummings Point Road, Stamford, CT.
- Disclosure of material stake: Reporting persons openly disclose a 7.6% ownership position (1,527,930 shares), meeting regulatory transparency requirements
- Position classified as passive: The filing is a Schedule 13G/A indicating the shares are held for investment, not to change or influence control
- No sole voting or dispositive power: Each reporting person reports 0 shares of sole voting and sole dispositive power, which may limit direct influence
- Shared control only: All reported authority is shared (1,527,930 shares), potentially diluting clear accountability for engagement
Insights
TL;DR: Point72-affiliated holders disclose a material 7.6% passive stake in CDTX held for investment, with shared voting power.
The Schedule 13G/A shows a notable institutional position: 1,527,930 shares (7.6%), reported as passive and held by Point72 Associates under management of Point72 Asset Management. The filing clarifies shared voting and dispositive power but no sole control, and includes the standard certification that the position is not intended to influence control of the issuer. For investors, an ownership stake above 5% from a hedge-fund-affiliated manager is material for liquidity and potential shareholder engagement, but the filing explicitly characterizes the position as passive.
TL;DR: Reporting persons disclose shared authority and classify the position as passive; no group formation or control claim is made.
The document identifies reporting persons (Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen) and states shared voting/dispositive power of 1,527,930 shares. There is no indication of a group seeking control, no identification of additional members, and the form is a 13G (passive). From a governance perspective, this filing signals ownership transparency without an immediate change in board-control dynamics.
Cidara Therapeutics, Inc. (CDTX) ha ricevuto una comunicazione Schedule 13G/A secondo cui entità affiliate a Point72 e Steven A. Cohen detengono beneficiariamente 1.527.930 azioni ordinarie, pari al 7,6% del capitale sociale in circolazione alla data del 30 giugno 2025. La dichiarazione indica che le azioni sono detenute a scopo d'investimento da Point72 Associates e che Point72 Asset Management e Point72 Capital Advisors esercitano congiuntamente il potere di voto e il potere dispositiv o sulle azioni; nessuno dei soggetti segnalanti dichiara poteri di voto o dispositivi esclusivi. L'indirizzo comunicato è 72 Cummings Point Road, Stamford, CT.
Cidara Therapeutics, Inc. (CDTX) recibió una presentación Schedule 13G/A que reporta que entidades afiliadas a Point72 y Steven A. Cohen poseen beneficiariamente 1.527.930 acciones ordinarias, lo que representa el 7,6% de la clase en circulación al 30 de junio de 2025. La presentación señala que esas acciones se mantienen con fines de inversión por Point72 Associates y que Point72 Asset Management y Point72 Capital Advisors comparten el poder de voto y el poder dispositi vo sobre las acciones; ninguno de los informantes reclama poder de voto o dispositi vo exclusivo. La dirección declarada es 72 Cummings Point Road, Stamford, CT.
Cidara Therapeutics, Inc. (CDTX)는 Point72 계열사들과 Steven A. Cohen이 1,527,930주의 보통주를 실질적으로 보유하고 있으며, 이는 2025년 6월 30일 기준 발행 주식의 7.6%에 해당한다고 보고하는 Schedule 13G/A를 접수했습니다. 제출서에는 해당 주식이 투자 목적으로 Point72 Associates 명의로 보유되어 있고 Point72 Asset Management 및 Point72 Capital Advisors가 해당 주식에 대한 공동의 의결권 및 처분권을 보유한다고 기재되어 있습니다; 보고인들 중 어느 누구도 단독 의결권이나 단독 처분권을 주장하지 않습니다. 보고된 주소는 72 Cummings Point Road, Stamford, CT입니다.
Cidara Therapeutics, Inc. (CDTX) a reçu un dépôt Schedule 13G/A indiquant que des entités affiliées à Point72 et Steven A. Cohen détiennent à titre bénéficiaire 1 527 930 actions ordinaires, représentant 7,6% de la catégorie en circulation au 30 juin 2025. Le document précise que ces actions sont détenues à des fins d'investissement par Point72 Associates et que Point72 Asset Management et Point72 Capital Advisors exercent conjointement le pouvoir de vote et le pouvoir de disposition sur ces actions ; aucun des déclarants ne revendique de pouvoir de vote ou de disposition exclusif. L'adresse déclarée est 72 Cummings Point Road, Stamford, CT.
Cidara Therapeutics, Inc. (CDTX) hat eine Schedule 13G/A eingereicht erhalten, die berichtet, dass Point72-nahe Einheiten und Steven A. Cohen wirtschaftlich 1.527.930 Aktien des Stammkapitals besitzen, was 7,6% der ausstehenden Aktienklasse zum 30. Juni 2025 entspricht. Die Einreichung besagt, dass diese Aktien von Point72 Associates zu Anlagezwecken gehalten werden und dass Point72 Asset Management und Point72 Capital Advisors gemeinsame Stimm- und Verfügungsrechte über die Aktien ausüben; keiner der meldenden Personen beansprucht alleiniges Stimm- oder Verfügungsrecht. Die angegebene Anschrift lautet 72 Cummings Point Road, Stamford, CT.